Loading
A phase 3 trial of Osimertinib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) is a phase 3 interventional study registered as NCT05629234 by AstraZeneca, with 37 participants enrolled, started 2023-05-08 and due to reach its primary completion in 2027-02-22. Interventions recorded: Osimertinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Parexel, AstraZeneca and the tag pipeline.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Parexel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/